Insulet stock (NASDAQ: PODD) currently trades around $200 per share, about 35% lower than the levels of over $300 seen in early November 2021. In comparison, its peer – DexCom stock – is down 55% over ...
PODD exhibits bullish price action with a series of higher highs and lows, trading above its upward sloping 30-week EMA since August 2024. Momentum is long-term bullish but short-term bearish, with ...
Insulet Corporation (NASDAQ:PODD) ranks among the best medical device stocks to invest in. Canaccord Genuity maintained its Buy rating on Insulet Corporation (NASDAQ:PODD) and boosted its price target ...
Insulet delivers strong fundamentals, with robust revenue growth, high margins, and impressive returns on capital, driven by Omnipod's success. PODD's Q3 results were strong, featuring record revenues ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback